All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma

BACKGROUND: Immunotherapies targeting CD38 have demonstrated salient efficacy in relapsed/refractory multiple myeloma (MM). However, loss of CD38 antigen and outgrowth of CD38 negative plasma cells have emerged as a major obstacle in clinics. All-trans retinoic acid (ATRA) has been reported to upreg...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Ziyi, Wang, Jingya, Guo, Jing, Li, Xin, Wang, Sheng, Xie, Ying, Jiang, Hongmei, Wang, Yixuan, Wang, Mengqi, Hu, Meilin, Li, Qian, Wang, Yafei, Mi, Jian-Qing, Liu, Zhiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016253/
https://www.ncbi.nlm.nih.gov/pubmed/36918219
http://dx.doi.org/10.1136/jitc-2022-006325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016253/
https://www.ncbi.nlm.nih.gov/pubmed/36918219
http://dx.doi.org/10.1136/jitc-2022-006325

Ejemplares similares